Reactive oxygen species deglycosilate glomerular α-dystroglycan

Kidney International

Volumn 69, Issue 9, 2006, Pages 1526-1534

  Vogtlander N P J ^a   Tamboer, W P M ^a   Bakker, M A H ^a   Campbell, K P ^b   Van Der Vlag, J ^a   Berden, J H M ^a,c  

^a RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

^b UNIVERSITY OF IOWA   (United States)

^c RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

Agrin; Dystroglycan; Glomerulus; Laminin; Podocyte; Radicals

Indexed keywords

AGRIN; ALPHA DYSTROGLYCAN; ANTIBODY; CARBOHYDRATE; DOXORUBICIN; EPITOPE; GLYCOPROTEIN; LAMININ; REACTIVE OXYGEN METABOLITE;

ADOLESCENT; ANIMAL MODEL; ANIMAL TISSUE; APICAL MEMBRANE; ARTICLE; ASSAY; BASOLATERAL MEMBRANE; CONTROLLED STUDY; COW; DEGLYCOSYLATION; DEPOLYMERIZATION; GLOMERULOPATHY; GLOMERULUS BASEMENT MEMBRANE; IN VITRO STUDY; IN VIVO STUDY; KIDNEY; LIGAND BINDING; LIGAND OVERLAY ASSAY; NEPHROTOXICITY; NONHUMAN; PODOCYTE; PRIORITY JOURNAL; PROTEIN BINDING; RAT; SOLID PHASE ASSAY;

AGRIN; ANIMALS; CATTLE; DOXORUBICIN; DYSTROGLYCANS; GLYCOSYLATION; KIDNEY FAILURE; KIDNEY GLOMERULUS; LAMININ; MUSCLE, SKELETAL; PODOCYTES; RABBITS; RATS; REACTIVE OXYGEN SPECIES; XANTHINE OXIDASE;

EID: 33646494644     PISSN: 00852538     EISSN: 15231755     Source Type: Journal    
DOI: 10.1038/sj.ki.5000138     Document Type: Article

References (51)

1. Raats CJ, van den Born J, Bakker MA et al. Expression of agrin, dystroglycan, and utrophin in normal renal tissue and in experimental glomerulopathies. Am J Pathol 2000; 156: 1749-1765.
2. Vogtlander NPJ, Dijkman H, Bakker MAH et al. Localization of alpha-dystroglycan on the podocyte: from top to toe. J Histochem Cytochem 2005; 53: 1345-1353.
3. Ervasti JM, Ohlendieck K, Kahl SD et al. Deficiency of a glycoprotein component of the dystrophin complex in dystrophic muscle. Nature 1990; 345: 315-319.
4. Ibraghimov-Beskrovnaya O, Ervasti JM, Leveille CJ et al. Primary structure of dystrophin-associated glycoproteins linking dystrophin to the extracellular matrix. Nature 1992; 355: 696-702.
5. Williamson RA, Henry MD, Daniels KJ et al. Dystroglycan is essential for early embryonic development: disruption of Reichert's membrane in Dag1-null mice. Hum Mol Genet 1997; 6: 831-841.
6. Durbeej M, Larsson E, Ibraghimov-Beskrovnaya O et al. Non-muscle alpha-dystroglycan is involved in epithelial development. J Cell Biol 1995; 130: 79-91.
7. Endo T. O-mannosyl glycans in mammals. Biochim Biophys Acta 1999; 1473: 237-246.
8. Ervasti JM, Campbell KP. Membrane organization of the dystrophin-glycoprotein complex. Cell 1991; 66: 1121-1131.
9. Gee SH, Blacher RW, Douville PJ et al. Laminin-binding protein 120 from brain is closely related to the dystrophin-associated glycoprotein, dystroglycan, and binds with high affinity to the major heparin binding domain of laminin. J Biol Chem 1993; 268: 14972-14980.
10. Bowe MA, Deyst KA, Leszyk JD, Fallon JR. Identification and purification of an agrin receptor from Torpedo postsynaptic membranes: a heteromeric complex related to the dystroglycans. Neuron 1994; 12: 1173-1180.
11. Ervasti JM, Burwell AL, Geissler AL. Tissue-specific heterogeneity in alpha-dystroglycan sialoglycosylation. Skeletal muscle alpha-dystroglycan is a latent receptor for Vicia villosa agglutinin b4 masked by sialic acid modification. J Biol Chem 1997; 272: 22315-22321.
12. Michele DE, Barresi R, Kanagawa M et al. Post-translational disruption of dystroglycan-ligand interactions in congenital muscular dystrophies. Nature 2002; 418: 417-422.
13. Longman C, Brockington M, Torelli S et al. Mutations in the human LARGE gene cause MDC1D, a novel form of congenital muscular dystrophy with severe mental retardation and abnormal glycosylation of {alpha}-dystroglycan. Hum Mol Genet 2003; 12: 2853-2861.
14. Martin-Rendon E, Blake DJ. Protein glycosylation in disease: new insights into the congenital muscular dystrophies. Trends Pharmacol Sci 2003; 24: 178-183.
15. Raats CJ, Bakker MA, van den Born J, Berden JH. Hydroxyl radicals depolymerize glomerular heparan sulfate in vitro and in experimental nephrotic syndrome. J Biol Chem 1997; 272: 26734-26741.
16. Diamond JR, Bonventre JV, Karnovsky MJ. A role for oxygen free radicals in aminonucleoside nephrosis. Kidney Int 1986; 29: 478-483.
17. Neale TJ, Ojha PP, Exner M et al. Proteinuria in passive Heymann nephritis is associated with lipid peroxidation and formation of adducts on type IV collagen. J Clin Invest 1994; 94: 1577-1584.
18. Shah SV. Evidence suggesting a role for hydroxyl radical in passive Heymann nephritis in rats. Am J Physiol 1988; 254: F337-344.
19. Rehan A, Johnson KJ, Wiggins RC et al. Evidence for the role of oxygen radicals in acute nephrotoxic nephritis. Lab Invest 1984; 51: 396-403.
20. Greiber S, Muller B, Daemisch P, Pavenstadt H. Reactive oxygen species alter gene expression in podocytes: induction of granulocyte macrophage-colony-stimulating factor. J Am Soc Nephrol 2002; 13: 86-95.
21. Neale TJ, Ullrich R, Ojha P et al. Reactive oxygen species and neutrophil respiratory burst cytochrome b558 are produced by kidney glomerular cells in passive Heymann nephritis. Proc Natl Acad Sci USA 1993; 90: 3645-3649.
22. Tay M, Comper WD, Vassiliou P et al. The inhibitory action of oxygen radical scavengers on proteinuria and glomerular heparan sulphate loss in the isolated perfused kidney. Biochem Int 1990; 20: 767-778.
23. Yoshioka T, Ichikawa I, Fogo A. Reactive oxygen metabolites cause massive, reversible proteinuria and glomerular sieving defect without apparent ultrastructural abnormality. J Am Soc Nephrol 1991; 2: 902-912.
24. Raats CJ, Bakker MA, Hoch W et al. Differential expression of agrin in renal basement membranes as revealed by domain-specific antibodies. J Biol Chem 1998; 273: 17832-17838.
25. Groffen AJ, Ruegg MA, Dijkman H et al. Agrin is a major heparan sulfate proteoglycan in the human glomerular basement membrane. J Histochem Cytochem 1998; 46: 19-27.
26. Kriz W, Lemley KV. The role of the podocyte in glomerulosclerosis. Curr Opin Nephrol Hypertens 1999; 8: 489-497.
27. Pavenstadt H, Kriz W, Kretzler M. Cell biology of the glomerular podocyte. Physiol Rev 2003; 83: 253-307.
28. Yu D, Petermann A, Kunter U et al. Urinary podocyte loss is a more specific marker of ongoing glomerular damage than proteinuria. J Am Soc Nephrol 2005; 16: 1733-1741.
29. Holt KH, Crosbie RH, Venzke DP, Campbell KP. Biosynthesis of dystroglycan: processing of a precursor propeptide. FEBS Lett 2000; 468: 79-83.
30. Smalheiser NR. Cranin interacts specifically with the sulfatide-binding domain of laminin. J Neurosci Res 1993; 36: 528-538.
31. Blank M, Blake DJ, Kroger S. Molecular diversity of the dystrophin-like protein complex in the developing and adult avian retina. Neuroscience 2002; 111: 259-273.
32. Pavoni E, Sciandra F, Barca S et al. Immunodetection of partially glycosylated isoforms of alpha-dystroglycan by a new monoclonal antibody against its beta-dystroglycan-binding epitope. FEBS Lett 2005; 579: 493-499.
33. Sugita S, Saito F, Tang J et al. A stoichiometric complex of neurexins and dystroglycan in brain. J Cell Biol 2001; 154: 435-445.
34. Kojima K, Davidovits A, Poczewski H et al. Podocyte flattening and disorder of glomerular basement membrane are associated with splitting of dystroglycan-matrix interaction. J Am Soc Nephrol 2004; 15: 2079-2089.
35. Pagtalunan ME, Miller PL, Jumping-Eagle S et al. Podocyte loss and progressive glomerular injury in type II diabetes. J Clin Invest 1997; 99: 342-348.
36. Lemley KV, Lafayette RA, Safai M et al. Podocytopenia and disease severity in IgA nephropathy. Kidney Int 2002; 61: 1475-1485.
37. Hara M, Yanagihara T, Kihara I. Urinary podocytes in primary focal segmental glomerulosclerosis. Nephron 2001; 89: 342-347.
38. Kim YH, Goyal M, Kurnit D et al. Podocyte depletion and glomerulosclerosis have a direct relationship in the PAN-treated rat. Kidney Int 2001; 60: 957-968.
39. Nakamura T, Ushiyama C, Suzuki S et al. Urinary podocytes for the assessment of disease activity in lupus nephritis. Am J Med Sci 2000; 320: 112-116.
40. Nakamura T, Ushiyama C, Hirokawa K et al. Effect of cerivastatin on proteinuria and urinary podocytes in patients with chronic glomerulonephritis. Nephrol Dial Transplant 2002; 17: 798-802.
41. Nakamura T, Ushiyama C, Hara M et al. Comparative effects of plasmapheresis and intravenous cyclophosphamide on urinary podocyte excretion in patients with proliferative lupus nephritis. Clin Nephrol 2002; 57: 108-113.
42. Vogelmann SU, Nelson WJ, Myers BD, Lemley KV. Urinary excretion of viable podocytes in health and renal disease. Am J Physiol Renal Physiol 2003; 285: F40-F48.
43. Raats CJ, Van Den Born J, Berden JH. Glomerular heparan sulfate alterations: mechanisms and relevance for proteinuria. Kidney Int 2000; 57: 385-400.
44. Regele HM, Fillipovic E, Langer B et al. Glomerular expression of dystroglycans is reduced in minimal change nephrosis but not in focal segmental glomerulosclerosis. J Am Soc Nephrol 2000; 11: 403-412.
45. Laemmli UK. Cleavage of structural proteins during the assembly of the head of bacteriophage T4. Nature 1970; 227: 680-685.
46. Spiro RG. Studies on the renal glomerular basement membrane. Preparation and chemical composition. J Biol Chem 1967; 242: 1915-1922.
47. Freytag JW, Ohno M, Hudson BG. Large scale preparation of bovine renal glomerular basement membrane in the presence of protease inhibitors. Prep Biochem 1978; 8: 215-224.
48. van den Born J, van den Heuvel LP, Bakker MA et al. A monoclonal antibody against GBM heparan sulfate induces an acute selective proteinuria in rats. Kidney Int 1992; 41: 115-123.
49. Yamada H, Denzer AJ, Hori H et al. Dystroglycan is a dual receptor for agrin and laminin-2 in Schwann cell membrane. J Biol Chem 1996; 271: 23418-23423.
50. Ervasti JM, Kahl SD, Campbell KP. Purification of dystrophin from skeletal muscle. J Biol Chem 1991; 266: 9161-9165.
51. Moseley R, Waddington R, Evans P et al. The chemical modification of glycosaminoglycan structure by oxygen-derived species in vitro. Biochim Biophys Acta 1995; 1244: 245-252.